Skip to main content
Dr Julie Fox

Professor Julie Fox

Lead Investigator

  • Reader HIV

Research interests

  • Immunology
  • Preventative medicine

Biography

Professor Julie Fox qualified from the University of Manchester and trained in Genitourinary Medicine at Imperial College London. Julie leads the HIV clinical trials unit at Guys and St Thomas’ NHS Trust and is a Professor in HIV Infection in the School of Immunology & Microbial Sciences at King's. Julie is also Chief Investigator on national and international multi-centre intervention studies collaborating with NHS/academic partners across the UK, Europe and Sub-Saharan Africa.

Her research focuses on HIV prevention (vaccine and pre-exposure prophylaxis), HIV cure and optimising HIV treatment. She collaborates widely and is a keen proponent of multidisciplinary research. Julie is co-founder of the UK HIV cure group: Collaborative HIV Eradication of Reservoirs: UK BRC (CHERUB) and leads the international combined HIV adolescent prevention group, CHAPS. Furthermore, she is trial physician of the international HIV vaccine and PrEP study, PREPVACC.

In the past year, Julie has carried out SARS-CoV-2 research. In addition, she co-led the HIV group of the Oxford COV002 vaccine trial and is leading a multidisciplinary research network across UK, Uganda and South Africa evaluating SARS-CoV-2 antibody evolution, developing a SARS-CoV-2 ex vivo challenge model and carrying out public engagement in rural communities (COVAB). She is Chief investigator of the COV-TT test and treat study and is collecting longitudinal samples from special populations to evaluate antibody response to vaccination (COVAB-B).

    Research

    CHAPS male participants
    Fox Group

    The Fox Group works on combined HIV adolescent prevention and investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in Sub-Saharan Africa and Europe.

    CHAPS Africa 1800 x 500 banner
    CHAPS (Combined HIV Adolescent Prevention Study)

    Combined HIV African Prevention Study: On-demand Truvada and F/TAF Pre-exposure and Post-exposure prophylaxis to protect adolescents from HIV

    News

    MOBILE MEN launched to support HIV prevention in East and Southern Africa

    The study aims to help men who are mobile for work, remain HIV negative through developing PrEP services specific to their needs

    MOBILEMEN-1

    King's study provides vital information to guide COVID-19 vaccine development

    The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

    A community COVID-19 testing site

    Spotlight

    Preventing new HIV infections through vital medication guidelines

    Research by King’s provides vital evidence on the efficacy of pre-exposure prophylaxis (PrEP)

    Copy of PrEP main

      Research

      CHAPS male participants
      Fox Group

      The Fox Group works on combined HIV adolescent prevention and investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in Sub-Saharan Africa and Europe.

      CHAPS Africa 1800 x 500 banner
      CHAPS (Combined HIV Adolescent Prevention Study)

      Combined HIV African Prevention Study: On-demand Truvada and F/TAF Pre-exposure and Post-exposure prophylaxis to protect adolescents from HIV

      News

      MOBILE MEN launched to support HIV prevention in East and Southern Africa

      The study aims to help men who are mobile for work, remain HIV negative through developing PrEP services specific to their needs

      MOBILEMEN-1

      King's study provides vital information to guide COVID-19 vaccine development

      The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

      A community COVID-19 testing site

      Spotlight

      Preventing new HIV infections through vital medication guidelines

      Research by King’s provides vital evidence on the efficacy of pre-exposure prophylaxis (PrEP)

      Copy of PrEP main